Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly
about
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsPhase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.mTORC1 and mTORC2 in cancer and the tumor microenvironment.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
P2860
Q28071388-549B1C38-FA26-461B-8399-2851D56D7A77Q28075606-7AA8B3DA-B13E-407E-9949-AD5C2C0AE863Q33433009-D056A878-B275-4554-8DB3-33B30F7CCFF2Q38790957-50989517-AFB7-40AD-A8FE-835FBE5CBA05Q38955246-7FE4891A-E40A-45FA-B867-B9A55942BB96Q38982579-F3E3DA47-F81E-4364-9F68-840D12C635E6Q39326047-8C46C525-0DCF-463F-BE11-8BB1543910F8Q39773825-E7FE2EF1-F539-46DF-B652-1C884DA907C5Q40575812-B7A8FE40-E9B8-4FCD-A0F2-45DB3E812F74Q41189355-502312BE-A97F-416C-9C37-E477F8147C4FQ48246561-983D3C01-39B2-4411-A7AE-905DB23AADCBQ53351504-5B0A9C3D-734B-46BF-9F5E-D68D4B009DBA
P2860
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@nl
type
label
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@nl
prefLabel
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@nl
P2093
P2860
P1433
P1476
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
P2093
Coumaran Egile
Drew Rasco
Frauke Bentzien
Jason Jiang
Kyriakos P Papadopoulos
Pau Abrisqueta
Rodrigo Ruiz-Soto
Weiliang Shi
P2860
P304
P356
10.3109/10428194.2014.974040
P577
2014-11-19T00:00:00Z